<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907348</url>
  </required_header>
  <id_info>
    <org_study_id>IIL_REAL07</org_study_id>
    <nct_id>NCT00907348</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma</brief_title>
  <acronym>REAL07</acronym>
  <official_title>Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter phase II pilot trial designed with the purpose of dose
      finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21
      (LR-CHOP21) for elderly patients with untreated Diffuse Large B Cell Lymphoma (DLBCL).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of adverse events according with Common Terminology Criteria for Adverse events (CTCAE)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohorts 1 - 2 - 3 - 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LR-CHOP21</intervention_name>
    <description>FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14
SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14
THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14
FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days</description>
    <arm_group_label>Cohorts 1 - 2 - 3 - 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understand and voluntarily sign an informed consent form

          2. Able to adhere to the study visit schedule and other protocol requirements

          3. Histologic subtypes as follows:

               -  CD20 positive Diffuse large B-Cell lymphoma

               -  CD20 positive Follicular grade IIIb

          4. Age 60-80

          5. Untreated patients. In patients with bulky mass or systemic symptoms or compressive
             disease or rapidly progressive adenopathies a pre-study treatment is allowed with
             steroids and/or a single dose of Vincristine 1.4 mg/mq (max 2) in the seven days prior
             the start of the study treatment

          6. Measurable and/or evaluable disease

          7. Ann Arbor stage II, III, IV

          8. International Prognostic Index at low-intermediate, intermediate-high, high risk
             (2/3/4-5)

          9. Adequate haematological counts: ANC &gt; 1.5 x 109/L and platelet count &gt; 75 x 109/L
             unless due to bone marrow involvement

         10. Conjugated bilirubin up to 2 x UNL

         11. Alkaline phosphatase and transaminases up to 2 x UNL

         12. Creatinine clearance &gt; 50 ml/min

         13. HIV negativity

         14. HCV negativity

         15. HBV negativity or patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative

         16. Cardiac ejection fraction (MUGA scan or echocardiography) &gt; 45%

         17. Non peripheral neuropathy or CNS disease. Non testicular Lymphoma

         18. Life expectancy &gt; 6 months

         19. Performance status &lt; 2 according to ECOG scale

         20. Comprehensive geriatric assessment (CGA) as outlined in Appendix 15 showing absence of
             any impairment in activity of daily living (ADL), of any condition defining a
             geriatric syndrome, and of any grade 4 comorbidity or of more than three grade 3
             comorbidities according to CIRS-G scale

         21. Disease free of prior malignancies for â‰¥ 3 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix
             or breast

         22. Females of childbearing potential (FCBP) must agree to use two reliable forms of
             contraception simultaneously or to practice complete abstinence from heterosexual
             intercourse during the following time periods related to this study: for at least 28
             days before starting study drug;while participating in the study; for at least 28 days
             after discontinuation from the study

               -  The two methods of reliable contraception must include one highly effective
                  method (i.e., intrauterine device (IUD), hormonal [birth control pills,
                  injections, or implants], tubal ligation, partner's vasectomy) and one additional
                  effective (barrier) method (i.e., latex condom, diaphragm, cervical cap)

               -  FCBP must be referred to a qualified provider of contraceptive methods if needed

        Exclusion Criteria:

          1. Lymphoblastic Lymphoma

          2. Burkitt Lymphoma

          3. Non Hodgkin lymphoma CD 20 negative

          4. Mantle Cell Lymphoma

          5. Follicular Non Hodgkin Lymphoma grade I-II-IIIa

          6. Primitive mediastinal diffuse large B cell lymphoma with only mediastinal involvement

          7. International Prognostic Index at low risk (1)

          8. Has known or suspected hypersensitivity or intolerance to Rituximab

          9. History of evolutive malignancy within the last 3 years other than squamous cell and
             basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast

         10. Extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy
             before enrollment within 3 years before the start of treatment

         11. Exposure to Rituximab prior to study entry

         12. Have received an experimental drug or used an experimental medical device within 4
             weeks before the planned start of treatment. Concurrent participation in non-treatment
             studies is allowed, if it will not interfere with participation in this study

         13. CNS disease (meningeal and/or brain involvement by lymphoma) or Testicular involvement

         14. DVT in the last year

         15. History of clinically relevant liver or renal insufficiency; significant cardiac,
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,
             hematologic, psychiatric, or metabolic disturbances

         16. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable
             dose for at least 3 months before first dose of study drug

         17. Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure
             (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina,
             clinically significant pericardial disease, or cardiac amyloidosis

         18. Creatinine clearance &lt; 50 ml/min

         19. Presence of major neurological disorders

         20. HIV positivity

         21. HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with
             HBV-DNA negative

         22. HCV positivity

         23. Active opportunistic infection

         24. Comprehensive geriatric assessment (CGA) as outlined in Appendix 15 showing presence
             of any impairment in activity of daily living (ADL), of any condition defining a
             geriatric syndrome, and of any grade 4 comorbidity or of more than three grade 3
             comorbidities according to CIRS-G scale

         25. Any other co-existing medical or psychological condition that would preclude
             participation in the study or compromise ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Vitolo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Sanitaria Ospedaliera-Universitaria S. Giovanni Battista - TORINO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisione di Ematologia Osp. SS. Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica A Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia UniversitÃ  Policlinico</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Seragnoli&quot; Polic.S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Osp. Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onco-Ematologia I.R.C.C.</name>
      <address>
        <city>Candiolo (TO)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia 1 Ospedale S. Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia II FacoltÃ  di Medicina e Chirurgia UniversitÃ  Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia UniversitÃ  Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia UniversitÃ  - Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di biotecnologie cellulari ed ematologia Ospedale Umberto I - La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia - Univ. Perugia Sede Terni,</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.Ematologia 1 AOU San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia 2 ASO San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Osp. Cardinale Panico</name>
      <address>
        <city>Tricase (LE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>Non Hodgkin Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

